Edwards Lifesciences Logo

Edwards Lifesciences at ESC 2022

Agenda page banner

Raising awareness of the new transcatheter toolbox emerging to support you in managing heart failure patients with mitral (MR) or tricuspid regurgitation (TR) no longer responding to medical therapy

Understanding the right patient to refer is a key question for transcatheter tricuspid interventions.

Our session saw leading heart failure specialists and interventionalists discuss the role of TR in heart failure, and how transcatheter interventions can be a safe and effective option to improve the quality of life for patients with HFrEF and HFpEF.

We'll soon upload key learnings from the session. In the meantime, you can see the full agenda below.

TTVr session

Sunday 28 Aug 2022 |
17:45 - 18:30 CET

HFpEF vs. HFrEF in patients with tricuspid regurgitation:
does it matter for TTVr?

Session title
Speaker
Session title

HF diagnosis & management beyond HFrEF in 2022


Speaker
Carolyn Lam

Professor Lam Su Ping Carolyn

Senior Consultant Cardiologist, National Heart Centre (Singapore)

Professor Lam serves as a Senior Consultant Cardiologist at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore.

She is a tenured full Professor at Duke-National University of Singapore. Professor Lam was appointed to the 2021 European Society of Cardiology Heart Failure Guidelines Task Force, and an International Honorary Fellow of the Heart Failure Society of America 2021. 

She has published >350 articles in reputable journals and has been recognised in the Clarivate Highly cited Researcher 2021 in the field of Clinical Medicine and as a World Expert by Expertscape’s PubMed-based algorithms. She serves as Associate Editor for Circulation and the European Journal of Heart Failure.

#
Session title

TR and the right ventricle


Speaker
Jeroen Bax

Professor Jeroen Bax

Interventional Cardiologist / Cardiologist, Leiden University Medical Center - Leiden (Netherlands) 

Jeroen Bax is a Professor in Cardiology and Director of Non-invasive Imaging and the Echo Laboratory in the Department of Cardiology at the Leiden University Medical Center. He was President of the European Society of Cardiology (ESC) and has led the ESC Congress Program Committee. 

Professor Bax has also authored more than 700 papers in international peer-reviewed journals and serves on the Editorial Boards of various journals including as Associate Editor for the Journal of the American College of Cardiology and Heart.

#
Session title

Is TR different across HF subtypes?


Speaker
Professor Andrew JS Coats

Professor Andrew Coats

President of the Heart Failure Association and Professor of Cardiology, University of  Warwick (UK)

Professor Andrew Coats is an Australian-British academic Cardiologist and Inventor. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney, Head of Cardiology of Imperial College, London, and Associate Medical Director and Director of Cardiology of the Royal Brompton and Harefield Hospitals, London. 

Professor Coats is Editor-in-Chief of the Cardiac Failure Review editorial board. He has published over 20 patents and more than 650 full research papers and has more than 100,000 career citations.

Professor Barry A Borlaug

Professor Barry A Borlaug

Professor of Medicine and Director of Circulatory Failure Research, Mayo Clinic, Rochester, Minnesota (USA)

Professor Borlaug is a board-certified Cardiologist, specialising in heart failure and invasive hemodynamic assessment. He has conducted and collaborated on a number of studies examining the mechanisms of exercise tolerance using both invasive and non-invasive methods in patients with heart failure. 

He is keenly interested in the pathophysiologic underpinnings for exercise tolerance and fatigue in heart failure, with a focus on heart failure with preserved ejection fraction.

Session title

Current evidence for tricuspid repair across HF subtypes


Speaker
Karl-Patrik Kresoja

Karl-Patrik Kresoja

 Heart Center Leipzig at University of Leipzig (Germany)

Dr. Kresoja studied medicine at the Medical University of Graz, Austria. He went on to complete his doctoral thesis as well as his first three years of residency at Charité Medical University Berlin. He then continued his training at the Heart Center Leipzig and has specialised in invasive hemodynamics as well as interventional treatment of tricuspid regurgitation.

Dr. Kresoja has authored more than 35 papers in international peer-reviewed journals. For his research work he has awarded several national and international prizes from the German Cardiac Society as well as the European Society of Cardiology.

Session title

Panel discussion – whole faculty


Speaker
Stefan Anker

Professor Stefan Anker

Professor of Cardiology, Department of Cardiology, Charité Campus Virchow-Klinikum,  Berlin (Germany)

Professor Anker studied medicine at Charité Medical School of Humboldt-University Berlin, Germany. He went on to complete his PhD at the National Heart and Lung Institute of Imperial College London, United Kingdom. Since then, he has had teaching appointments in several countries including the UK, Germany, Australia and Italy.

Professor Anker has authored more than 1,000 articles and was named Highly Cited Researcher 2015–2020. He has won several prizes for his work, including the 2018 Copernicus Prize of German DFG & Polish FNP. In October 2020, he was awarded a Doctor honoris causa of Medical University Wroclaw, Poland.

He was the Vice President of the European Society of Cardiology (ESC, 2016–18), serving on the board  2012–2018. Dr. Anker has served in the board of the Heart Failure Association (HFA) of the ESC since 2006.  He is founding Editor-in-Chief of the journal ESC Heart Failure.

#
Discover what TAVI is doing

Discover what TAVI is doing

Stay up to date with current research developments and clinical insights in aortic stenosis (AS) and transcatheter aortic valve implantation (TAVI)

Learn more
Back

AS, aortic stenosis; ESC, European Society of Cardiology; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MR, mitral regurgitation; TAVI, transcatheter aortic valve implantation; TMTT, transcatheter mitral and tricuspid therapies; TR, tricuspid regurgitation; TTVr, transcatheter tricuspid valve repair.

Medical device for professional use.  For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult https://eifu.edwards.com/eifu )

Instructions For Use / Operator's Manual  where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, PASCAL, PASCAL Ace, and PASCAL Precision are trademarks or services marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners